Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new lab method developed at the NIH's National Cancer Institute can generate up to 1.5 billion specialized immune cells — called cDC1 dendritic cells — from a single mouse, yielding 75x more cells than previous techniques. These cells play a key role in fighting tumors and infections. The breakthrough could supercharge vaccine research and tumor immunology studies.
Researchers at the National Cancer Institute have developed a new culture system that solves a long-standing bottleneck in immunology: the scarcity of conventional type 1 dendritic cells (cDC1s). These immune cells are critical for activating the body's defenses against tumors and intracellular pathogens, but they're notoriously rare in living organisms — making large-scale research a serious challenge.
The new system, called induced cDC1 (iDC1) cultures, uses a 23-day protocol with three cytokines — FLT3L, low-dose GM-CSF, and Kit ligand — to coax mouse bone marrow into producing massive quantities of highly pure cDC1 cells. The resulting cells aren't just plentiful; they're functionally robust, capable of cross-presenting antigens to CD8+ T cells and secreting immune-activating molecules after stimulation.
By the Numbers:
95% purity of target cells in the final culture
Why it matters: This scalable, reproducible method gives researchers a reliable supply of high-quality cDC1 cells for studies in antigen processing, vaccine development, and cancer immunology. While the current system is mouse-based, the team hopes to eventually adapt it for human cells — a step that could open doors to clinical and translational applications.
